来源：环球网 "粘膜免疫机制尚未完全阐明，成为限制疫苗防感染效果的原因之一，而基础免疫研究的不足，限制了 高效、长效疫苗的研发。"12月20日，一场围绕"如何提高疫苗有效性与安全性，并最终共同推动生命与 健康产业进步"的专场讨论，在"好望角科学沙龙"上展开。 "好望角科学沙龙"以《科研之道：从病原基础研究到传染病防控应用》为主题在上海举办第九期活动， 生命科学领域专家学者、科技企业创始人、投资机构负责人等130余人参与，共同探讨病原基础研究到 传染病防控应用的最新科研成果、转化及投资逻辑，探索生命科学多元化发展路径。 病原微生物与免疫学家、中国科学院院士高福作为本期沙龙的主讲嘉宾，发表了题为《科研之道：从病 原基础研究到传染病防控应用》的主旨演讲。他表示："展望未来，能发展成大规模病情的病毒，不是 流感病毒就是冠状病毒。" 他表示，这主要基于两点考虑，一是这两种病毒均属于呼吸道病毒，这类病毒难以通过公共卫生有效干 预；二是这两类病毒更容易发生变异。 高福院士长期从事病原微生物跨宿主传播、感染机制与宿主细胞免疫研究及公共卫生政策与全球健康策 略研究，在流感、莫斯、埃博拉、寨卡、基孔肯亚、新冠和猴痘等病毒研究中取 ...

中新网广州12月21日电 (记者 蔡敏婕)带状疱疹并非老年人"专属疾病"，免疫功能受损的中青年群体同 样面临较高发病风险。 由广东省预防医学会主办的"2025年广东省疾病防控能力提升学习班"20日在广州举行，强调需重点关注 免疫缺陷人群与慢性基础病患者的疫苗接种工作，通过医防融合提升疾病防控水平。 广东省人民医院风湿免疫科主任医师李玲指出，带状疱疹的高危人群主要分为两类，一类是本身免疫监 视功能降低的患者，涵盖风湿免疫科疾病、血液肿瘤、实体瘤等人群；另一类是因治疗需要使用糖皮质 激素、免疫抑制剂、生物制剂等药物的群体，这类药物会进一步削弱人体免疫功能，提升感染风险。 "以往大家普遍认为带状疱疹是老年病，现在发现只要免疫功能受损，18岁以上的中青年群体也可能患 病。"李玲解释，带状疱疹由水痘-带状疱疹病毒再激活引发，小时候得过水痘的人，病毒会潜伏在体内 神经节中，当免疫功能下降时，病毒就可能被激活，从而引发带状疱疹。 疫苗接种是预防带状疱疹最有效的手段。不过李玲特别提醒，免疫缺陷人群在疫苗选择上有特殊要求， 风湿免疫科临床不推荐使用减毒活疫苗，建议优先选择灭活疫苗或重组疫苗，这类疫苗安全性更高，不 易诱发疾病复 ...

Core Viewpoint - TianKang Pharmaceutical Co., Ltd. continues to face declining performance in the first three quarters of the year, with high accounts receivable and low capacity utilization, raising concerns from regulatory authorities regarding its expansion plans [1] Financial Performance - Revenue and net profit have declined for two consecutive years, with revenues of 1 billion yuan, 1.055 billion yuan, and 1.052 billion yuan from 2022 to 2024, and net profits of 204 million yuan, 165 million yuan, and 153 million yuan during the same period, reflecting year-on-year declines of 18.36% and 11.20% respectively [3] - For the first nine months of 2025, the company reported a year-on-year revenue decline of 20.49% and a net profit decline of 42.44%, while comparable companies in the industry saw average revenue growth of 1.60% and net profit growth of 49.06% [4] Accounts Receivable - The company's accounts receivable at the end of the reporting periods were 338 million yuan, 377 million yuan, and 364 million yuan, accounting for 10.40%, 10.70%, and 10.95% of total assets respectively [7] - As of June 2025, accounts receivable stood at 482 million yuan, with 72.32% from government procurement clients, and overdue amounts from direct sales and distribution clients totaling 42.81 million yuan [7] Capacity Utilization and Expansion Plans - The company plans to raise 527 million yuan for various projects, including 128 million yuan for the expansion of veterinary vaccine production and 105 million yuan for the renovation of brucellosis vaccine production [9] - The current production capacity for brucellosis vaccine is 150 million doses, with capacity utilization rates of 36.02%, 43.72%, 44.44%, and 34.61% over the reporting period [11] - Regulatory authorities have questioned the necessity and rationale for expanding production given the low overall capacity utilization and have requested further analysis of market demand for the new capacity [11][12]